Cargando…
Liquid Biopsy-Based Exo-oncomiRNAs Can Predict Prostate Cancer Aggressiveness
SIMPLE SUMMARY: The main problem encountered in the management of prostate cancer (PCa) is the inability to distinguish slow-growing indolent tumors from aggressive tumors. It is therefore important to explore non-invasive assays for the early detection of this aggressive subtype, when it can still...
Autores principales: | Ruiz-Plazas, Xavier, Altuna-Coy, Antonio, Alves-Santiago, Marta, Vila-Barja, José, García-Fontgivell, Joan Francesc, Martínez-González, Salomé, Segarra-Tomás, José, Chacón, Matilde R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826893/ https://www.ncbi.nlm.nih.gov/pubmed/33440913 http://dx.doi.org/10.3390/cancers13020250 |
Ejemplares similares
-
Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness
por: Ruiz-Plazas, Xavier, et al.
Publicado: (2019) -
HDAC inhibitor misprocesses bantam oncomiRNA, but stimulates hid induced apoptotic pathway
por: Bhadra, Utpal, et al.
Publicado: (2015) -
Which statistical significance test best detects oncomiRNAs in cancer tissues? An exploratory analysis
por: Tang, Wei, et al.
Publicado: (2016) -
Serum Levels of the Cytokine TWEAK Are Associated with Metabolic Status in Patients with Prostate Cancer and Modulate Cancer Cell Lipid Metabolism In Vitro
por: Altuna-Coy, Antonio, et al.
Publicado: (2021) -
MicroRNA-130b functions as an oncomiRNA in non-small cell lung cancer by targeting tissue inhibitor of metalloproteinase-2
por: Hirono, Takayuki, et al.
Publicado: (2019)